Navigation Links
Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study

Approximately 60 Percent of Patients Reached American Diabetes Association's Recommended Average Blood Sugar Level

PRINCETON, N.J., May 8 /PRNewswire/ -- Novo Nordisk today announced results from the TITRATE(R) study showing that Levemir(R) (insulin detemir [rDNA origin] injection), taken once-daily, substantially lowered average blood sugar. Type 2 diabetes patients took a more active role in their treatment by adjusting their own dosing, after being trained and given an adjustment schedule by their physician. Approximately 60 percent of patients taking Levemir(R) once-daily reached the American Diabetes Association's (ADA) recommended average blood sugar level.

To view the Multimedia News Release, go to:

"Teaching and empowering patients to adjust their own insulin doses can help them achieve good blood sugar control," said Lawrence Blonde, MD, Director, Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Diabetes and Metabolism at the Ochsner Medical Center, New Orleans and the lead researcher in the trial. "These findings showed that following a self-adjustment dosing schedule of Levemir(R) once-daily resulted in a majority of patients reaching the target blood sugar level that the ADA recommends for most patients."

The TITRATE(R) study was published this week online in the journal, Diabetes, Obesity & Metabolism.

Patients who had not previously used insulin and had a starting average blood sugar level (A1C) of less than 9 percent, adjusted their dose of Levemir(R) to reach specific fasting blood sugar targets of 70-90 mg/dL or 80-110 mg/dL. Fasting blood sugar is the amount of sugar in the blood as determined by a blood test (called FPG) taken first thing in the morning after not eating for at least 8 hours. The study showed that Levemir(R) taken once-daily substantially lowered patients' A1C levels after 20 weeks for both FPG targets tested.

In the study, 64.3 percent of patients in the 70-90 mg/dL FPG target treatment group and 54.5 percent of patients in the 80-110 mg/dL FPG target group reached the ADA recommended A1C level of less than 7 percent. A1C levels in the 70-90 mg/dL group decreased by 1.2 percent to an average A1C of 6.77 percent; A1C levels in the 80-110 mg/dL group decreased by 0.9 percent to an average A1C level of 7 percent.

"Good blood sugar control is important in managing diabetes, and the more active a role patients can play, the better," said Alan Moses, Vice President and Global Chief Medical Officer at Novo Nordisk. "This study is exciting because it showed that Levemir(R) at a once-daily dose helped these patients manage their condition, and in doing so, helped them achieve substantial A1C reductions."

Rates of minor hypoglycemic events were low and comparable between the two treatment groups (5.09 vs 3.16 events/patient/year in the 70-90 mg/dL and 80-110 mg/dL FPG target treatment groups, respectively). A single major hypoglycemic event (requiring third party assistance) was reported by a patient in the 70-90 mg/dL FPG target treatment group. More details about the study can be found in the journal. Prescribing information for Levemir(R) is available by contacting Novo Nordisk or visiting

About the Study

The open-label TITRATE(R) study was a prospective, randomized, controlled study to examine the effect of patients self dosing of Levemir(R) once-daily using two FPG targets on blood sugar control. In the study, 244 type 2 diabetes patients taking oral antidiabetes drugs, who had never before used insulin, were assigned to one of two treatment groups: using 70-90 mg/dL or 80-110 mg/dL as their fasting blood sugar targets. After being trained and given an adjustment schedule by their physician, patients continued their use of oral diabetes drugs and changed their insulin dose every three days. Levemir(R) was initiated at 0.1 to 0.2 unit/kg or 10 units once-daily at dinner or bedtime.

About Levemir(R) (insulin detemir [rDNA origin] injection)

Levemir(R) is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir(R) is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir(R). As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir(R) is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir(R) should not be diluted or mixed with any other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir(R) from other intermediate or long-acting insulin preparations. The dose of Levemir(R) may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3 percent to 4 percent of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation. Less common, but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.

Levemir(R) is a registered trademark of Novo Nordisk A/S.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

For more information on the Ochsner Medical Center, go to

(C) Novo Nordisk Inc. 137944 May 2009

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
2. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
3. Video and Photo: Leading CEOs Launch Alliance With American Red Cross to Strengthen Nations Preparedness for Disasters
4. Video and Photo: U.S. Department of Health & Human Services and Ad Council Join NFL to Combat Childhood Obesity
5. Photo: Introducing a New Line of Baby and Toddler Shirts that Can Help Protect Innocent Babies During Flu Season
6. Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies
7. Photo: New York Goes Orange for Pumpkin Festival and Lupus Awareness Month
8. Photo: Scientists Complete Genome Sequence of Fungus Responsible for Dandruff, Skin Disorders
9. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
10. Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles
11. Photo: KFC Colonel Original and Look-a-Like Share Eye Treatment Success Story
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: